Angelo V Marzano
Overview
Explore the profile of Angelo V Marzano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
1696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valtellini L, Sechi A, Marzano A, Ferrucci S
Clin Exp Dermatol
. 2025 Feb;
PMID: 39994002
No abstract available.
2.
Gallo G, Ribero S, Ortoncelli M, Valtellini L, Marzano A, Quaglino P, et al.
Int J Dermatol
. 2025 Feb;
PMID: 39923193
No abstract available.
3.
Barei F, Calzari P, Pezzolo E, Napolitano M, Rossi M, Guanti M, et al.
Clin Exp Dermatol
. 2025 Feb;
PMID: 39899459
Background: Tralokinumab has demonstrated efficacy in the treatment atopic dermatitis (AD) in both clinical trials and real-world settings. However, limited data exists on the long-term use of tralokinumab in real-world...
4.
Tavoletti G, Lasagni G, Fabbri V, Bellocchi C, Marzano A, Ferrucci S
Ital J Dermatol Venerol
. 2025 Feb;
159(6):685-687.
PMID: 39898383
No abstract available.
5.
Valenti M, Ibba L, Di Giulio S, Gargiulo L, Malagoli P, Balato A, et al.
J Dermatolog Treat
. 2025 Jan;
36(1):2456532.
PMID: 39870384
Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective...
6.
Vignoli C, Gargiulo L, Ibba L, Balato A, Barbareschi M, Barruscotti S, et al.
J Dermatolog Treat
. 2025 Jan;
36(1):2444494.
PMID: 39761973
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over...
7.
Murgia G, Valtellini L, Nazzaro G, Passoni E, Scarfi F, Boggio F, et al.
Case Rep Oncol Med
. 2024 Dec;
2024:8947861.
PMID: 39717410
This case series highlights the complexity of sarcoidosis-like reactions (SLRs) during cancer treatment, specifically in patients receiving immunotherapy or targeted therapies for melanoma. SLRs can either mimic disease progression or...
8.
Calabrese L, Romagnuolo M, DOnghia M, Rubegni P, Marzano A, Moltrasio C
Exp Dermatol
. 2024 Dec;
33(12):e70022.
PMID: 39704328
Sweet syndrome (SS), originally described as acute febrile neutrophilic dermatosis, is a rare inflammatory skin condition, considered the prototype of neutrophilic dermatoses. It is characterised by the sudden onset of...
9.
Mariotti F, Pira A, De Luca N, Giampetruzzi A, Russo F, Cerri A, et al.
Front Immunol
. 2024 Dec;
15:1494294.
PMID: 39676877
Background: Bullous pemphigoid (BP) and mucous membrane pemphigoid (MMP) are rare autoimmune blistering disorders characterized by autoantibodies (autoAbs) targeting dermo-epidermal junction components such as BP180 and BP230. The differential diagnosis,...
10.
Termini D, Tavoletti G, Chiei-Gallo A, Avallone G, Boggio F, Marzano A, et al.
Int J Dermatol
. 2024 Dec;
PMID: 39668419
No abstract available.